The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.
Samantha Mary Jaglowski
Research Funding - Pharmacyclics
Jeffrey Alan Jones
Consultant or Advisory Role - Janssen; Pharmacyclics
Research Funding - Pharmacyclics
Joseph M. Flynn
No relevant relationships to disclose
Leslie A. Andritsos
No relevant relationships to disclose
Kami J. Maddocks
Research Funding - Pharmacyclics
Jennifer Ann Woyach
Consultant or Advisory Role - Pharmacyclics (U)
Kristie A. Blum
No relevant relationships to disclose
Michael R. Grever
Research Funding - NCI
Expert Testimony - Pharmacyclics (U)
Susan Michelle Geyer
No relevant relationships to disclose
Nyla A. Heerema
Research Funding - Pharmacyclics
Gerard Lozanski
No relevant relationships to disclose
Mona Stefanos
No relevant relationships to disclose
Nathan Hall
No relevant relationships to disclose
Veena Nagar
No relevant relationships to disclose
Brian Munneke
Employment or Leadership Position - Pharmacyclics
Jamie-Sue West
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Jutta Neuenburg
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Danelle Frances James
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Amy J. Johnson
No relevant relationships to disclose
John C. Byrd
Research Funding - Pharmacyclics